What is the Return on Assets (ROA) of FibroGen this year?
The Return on Assets (ROA) of FibroGen is -0.67 undefined this year.
FibroGen ROA 2024
FibroGen ROA
-0.67
Ticker
FGEN
ISIN
US31572Q8087
WKN
A12EZ0
In 2024, FibroGen's return on assets (ROA) was -0.67, a 39.41% increase from the -0.48 ROA in the previous year.
FibroGen Aktienanalyse
What does FibroGen do?
FibroGen Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for life-threatening diseases. The company is headquartered in San Francisco, California, with offices in China and Europe. Since its founding in 1993, the company has undergone remarkable development. It was founded by three doctors, Dr. Thomas B. Neff, Dr. Michael W. Loberg, and Dr. Gerald L. McMahon, who specialized in fibrosis and gene therapy. From the beginning, the company focused on research on therapies for diseases caused by abnormal connective tissue or fibrosis. FibroGen's business model is based on the innovation of therapies for the treatment of various diseases. The company has developed unique solutions that can improve the quality of life for people with severe chronic illnesses. To expand its business, FibroGen is supported by renowned partners, including Astellas Pharma, AstraZeneca, and Roche. FibroGen now has three business areas: biopharmaceuticals, China, and partnerships. In the biopharmaceuticals field, the company focuses on the development of therapies for the treatment of anemia in chronic kidney disease and idiopathic pulmonary fibrosis. One candidate, Roxadustat, is already approved in China and Japan and is currently being studied in clinical trials in the United States and Europe. Another candidate, Pamrevlumab, is marketed for the treatment of idiopathic pulmonary fibrosis. The Chinese market is particularly important for FibroGen, as the company has been active there since the early 2000s and has a subsidiary, FibroGen (China) Medical Technology Development Co., Ltd. FibroGen has also signed an agreement with AstraZeneca in China to jointly develop and market Roxadustat. FibroGen's partnership business focuses on developing targeted therapies for diseases in collaboration with other pharmaceutical companies. Genentech, a subsidiary of Roche, is one of FibroGen's largest partners. The two companies work together to develop therapies for the treatment of diabetic retinopathy. FibroGen has made significant progress in recent years and received many awards. For example, in 2020, the company received the Prix Galien USA in the category of "Best Biopharmaceutical," an award for innovative drugs in improving public health. In summary, FibroGen is an innovative biopharmaceutical company focused on the development and commercialization of therapies for life-threatening diseases. The company's business model is focused on collaborations with partners to develop targeted therapies. With its subsidiaries in China and Europe, FibroGen can offer therapeutic solutions worldwide. FibroGen ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding FibroGen's Return on Assets (ROA)
FibroGen's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing FibroGen's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider FibroGen's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in FibroGen’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about FibroGen stock
What was the ROA of FibroGen compared to the previous year?
The ROA of FibroGen has increased by 39.41% compared to the previous year.
What consequences do high ROA have for investors of FibroGen?
A high ROA is advantageous for investors of FibroGen, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in FibroGen?
A low ROA can be unfavorable for investors of FibroGen as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of FibroGen affect the company?
An increase in ROA of FibroGen can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of FibroGen impact the company?
A reduction in the ROA of FibroGen can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of FibroGen?
Some factors that can influence the ROA of FibroGen include revenue, operating costs, asset structure, and industry average.
Why is the ROA of FibroGen important for investors?
The ROA of FibroGen is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can FibroGen take to improve ROA?
To improve ROA, FibroGen can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does FibroGen pay?
Over the past 12 months, FibroGen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, FibroGen is expected to pay a dividend of 0 USD.
What is the dividend yield of FibroGen?
The current dividend yield of FibroGen is .
When does FibroGen pay dividends?
FibroGen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of FibroGen?
FibroGen paid dividends every year for the past 0 years.
What is the dividend of FibroGen?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is FibroGen located?
FibroGen is assigned to the 'Health' sector.
Wann musste ich die Aktien von FibroGen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of FibroGen from 10/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/22/2024.
When did FibroGen pay the last dividend?
The last dividend was paid out on 10/22/2024.
What was the dividend of FibroGen in the year 2023?
In the year 2023, FibroGen distributed 0 USD as dividends.
In which currency does FibroGen pay out the dividend?
The dividends of FibroGen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The FibroGen stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von FibroGen
Our stock analysis for FibroGen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of FibroGen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
